drugset / Trial / NCT01184079

Randomized Trial of Alternative HPV Vaccination Schedules in Males in a University Setting

NCT01184079 ↗

RandomizedParallel-groupOpen-labelPrevention

Summary

The investigators propose a randomized, open label trial of the immunogenicity of HPV vaccine among males 18-24 years old, comparing an on-time administration of the third dose with delayed administration of the third dose. All participants would receive the first and second doses according to schedule. They would be randomized to either Dose 3 at 6 months or Dose 3 at 12 months. Hypothesis: The Geometric mean titers in the 12 month test group (T) are non-inferior to the usual timing control group (C): H0: δ ≤ -δ0 versus H1: δ \> -δ0 where δ = log (GMTT )- log (GMTC) and δ0 is the pre-specified non-inferiority margin

Timeline

Start
2010-10
Primary completion
2012-05
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Quadrivalent human papillomavirus vaccine Vaccine 0.5 ml —

Indications

No indication recorded.